AUTHOR=Ferreira Daniel , Rivero-Santana Amado , Perestelo-Pérez Lilisbeth , Westman Eric , Wahlund Lars-Olof , Sarría Antonio , Serrano-Aguilar Pedro 

TITLE=Improving CSF Biomarkers’ Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer’s Disease by Considering Different Confounding Factors: A Meta-Analysis

JOURNAL=Frontiers in Aging Neuroscience

VOLUME=6

YEAR=2014

URL=https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2014.00287

DOI=10.3389/fnagi.2014.00287

ISSN=1663-4365

ABSTRACT=<p><bold>Background:</bold> Cerebrospinal fluid (CSF) biomarkers’ performance for predicting conversion from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) is still suboptimal.</p><p><bold>Objective:</bold> By considering several confounding factors we aimed to identify in which situations these CSF biomarkers can be useful.</p><p><bold>Data Sources:</bold> A systematic review was conducted on MEDLINE, PreMedline, EMBASE, PsycInfo, CINAHL, Cochrane, and CRD (1990–2013).</p><p><bold>Eligibility Criteria:</bold> (1) Prospective studies of CSF biomarkers’ performance for predicting conversion from MCI to AD/dementia; (2) inclusion of Aβ42 and T-tau and/or p-tau. Several meta-analyses were performed.</p><p><bold>Results:</bold> Aβ42/p-tau ratio had high capacity to predict conversion to AD in MCI patients younger than 70 years. The p-tau had high capacity to identify MCI cases converting to AD in ≤24 months.</p><p><bold>Conclusions:</bold> Explaining how different confounding factors influence CSF biomarkers’ predictive performance is mandatory to elaborate a definitive map of situations, where these CSF biomarkers are useful both in clinics and research.</p>